OBJECTIVES: Extracorporeal life support (ECLS) is an emerging option to treat selected @entity1 with @entity1167 refractory to cardiopulmonary resuscitation (CPR). Our primary objective was to determine the mortality at 30  days and at hospital discharge among adult @entity1 receiving veno-arterial ECLS for refractory @entity1167 . Our secondary objectives were to determine the 1-year survival and the health-related quality of life, and to examine factors associated with 30-day mortality. METHODS: In a retrospective, single-center investigation within a tertiary referral center, we analyzed the prospectively collected data of 49 @entity1 rescued from refractory @entity1167 through emergent implantation of ECLS (E-CPR) (18.1% of our overall ECLS activity, 2005-2013), implanted in-hospital and during ongoing external cardiac massage in all cases. A prospective follow-up with administration of the Medical Outcomes Study 36-Item Short-Form Health Survey (SF-36) questionnaire was performed. RESULTS: The mean age was 47.6      1.6  years; out-of-hospital @entity1167 occurred in 12% of cases; average low-flow time was 47.2      33  minutes; causes of @entity1167 were @entity299 (61.2%), @entity130 (14.3%), @entity1576 (4.1%), @entity295 (2%), and miscellaneous (18.4%). PRIMARY OBJECTIVE: Rates of survival at E-CPR explantation and at 30  days were 42.9% and 36.7%, respectively; @entity1620 occurred in 24.5% of cases. Secondary objectives: Increased simplified acute physiology score; higher serum @entity880 levels and lower body temperature at the time of implantation were associated with 30-day mortality. Bridge to heart transplantation or implantation of a long-term ventricular assist device was performed in 8.2%. No @entity204 occurred during the follow-up after discharge (36.7% survival; average follow-up was 15.6      19.2  months). The average Physical Component Summary and Mental Component Summary scores (SF-36 questionnaire) were, respectively, 45.2      6.8 and 48.3      7.7 among survivors. CONCLUSIONS: Extracorporeal cardiopulmonary resuscitation is a viable treatment for selected @entity1 with @entity1167 refractory to CPR. In our series, approximately one third of rescued @entity1 were alive at 6  months and presented quality-of-life scores comparable to those previously observed in @entity1 treated with ECLS.

Survival and quality of life after extracorporeal life support for refractory XXXX : A case series.

@entity1 :: ('9606', 'Species') :: ['patients'] @entity295 :: ('MESH:D018805', 'Disease') :: ['sepsis'] @entity1620 :: ('MESH:D001926', 'Disease') :: ['brain death'] @entity1576 :: ('MESH:D012131', 'Disease') :: ['respiratory disease'] @entity880 :: ('MESH:D019344', 'Chemical') :: ['lactate'] @entity299 :: ('MESH:D006331', 'Disease') :: ['heart disease'] @entity1167 :: ('MESH:D006323', 'Disease') :: ['cardiac arrest'] @entity204 :: ('MESH:D003643', 'Disease') :: ['deaths'] @entity130 :: ('MESH:D014947', 'Disease') :: ['trauma']
@entity1167 :: (MESH:D006323,Disease) :: ['cardiac arrest']
